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Abstract
There is strong evidence in literature supporting the benefit of monitoring plasma 
concentrations of -lactam antibiotics in the critically ill to ensure appropriateness of dosing. 
The objective of this work was to develop a method for the simultaneous determination of 
total concentrations piperacillin, benzylpenicillin, flucloxacillin, meropenem, ertapenem, 
cephazolin and ceftazidime in human plasma. Sample preparation involved protein 
precipitation with acetonitrile containing 0.1% formic acid and subsequent dilution of 
supernatant with 0.1% formic acid in water. Chromatographic separation was achieved on a 
reversed phase column (C18, 2.6µm, 2.1* 50 mm) via gradient elution using water and 
acetonitrile, each containing 0.1% formic acid, as mobile phase. Tandem mass spectrometry 
(MSMS) analysis was performed, after electrospray ionization in the positive mode, with 
multiple reaction monitoring (MRM). The method is accurate with the inter-day and intra-day 
accuracies of quality control samples (QCs) ranging from 95%-107% and 95%-108%, 
respectively. It is also precise with intra-day and inter-day coefficient of variations ranging 
from 4 to 12 % and 5-14% respectively. The lower limit of quantification was 0.1g/mL for 
each antibiotic except flucloxacillin (0.25g/mL). Recovery was greater than 96% for all 
analytes except for ertapenem (78%). Coefficients of variation for the matrix effect were less 
than 10% over the six batches of plasma. Analytes were stable over three freeze-thaw cycles, 
and for reasonable hours on the bench top as well as post-preparation. This novel liquid 
chromatography tandem mass spectrometry method proved accurate, precise and applicable 
for therapeutic drug monitoring and pharmacokinetic studies of the selected -lactam 
antibiotics.
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Highlights
 We present a method for simultaneous determination of seven beta-lactams in plasma
 The selected antibiotics are those commonly used in critically ill patients 
 The method is accurate, precise and meets validation requirements by guidelines   
 It proved applicable for therapeutic drug monitoring and pharmacokinetic studies  
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1. Introduction
Severe infection and associated sepsis remain the most common causes of morbidity and 
mortality in critically ill patients worldwide [1]. Despite tremendous investments in new 
treatments, arresting poor clinical outcomes has been a global challenge [2]. For -lactam 
antibiotics, which are the mainstay of therapy in severely ill patents, emerging evidence 
suggest that poor antibiotic exposure is a potential cause of poor clinical outcomes [3-5]. 
Therefore, optimising antibiotic dosing may be a key intervention to improve clinical 
outcomes. This is further supported by studies that correlate optimised antibiotic exposure 
with improved patient outcome [6-12]. 
However, optimization of antibiotic dosing is not an easy exercise. The pharmacokinetics of 
-lactam antibiotics is difficult to predict in the critically ill patient population due to the 
unpredictable effects of pathophysiologic processes particularly during sever sepsis and 
malignancy [13,14].  The drug’s apparent volume of distribution and clearance may be 
elevated leading to sub-therapeutic plasma concentrations [4,15-24]. On the other hand 
clearance may be unchanged [17] or decreased [4,18] and in the presence of organ 
dysfunction such acute kidney injury, diminished clearance may lead to massive 
accumulation and toxicity [25-27]. In patients with renal dysfunction, optimization antibiotic 
dosing is further complicated by the use of renal replacement therapy which provides 
significant and variable extracorporeal clearance for several -lactams [28-34]. These 
pharmacokinetic challenges would mean that empiric fixed dose strategy is unlikely to ensure 
sufficient antibiotic exposure and as well empiric dose optimization is unrealistic due the 
little data available to guide clinicians. 
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Confirmation of dosing appropriateness through monitoring of plasma concentrations is 
therefore essential for -lactam antibiotics in the critically ill patient population. Routine 
therapeutic drug monitoring (TDM), enables a rational, patient specific dose adjustment 
thereby maximizing treatment efficacy while minimizing drug toxicity [35]. Even though it is 
has not yet been a standard practice across the world, studies have demonstrated the clinical 
utility of this methodology in critically ill patients [12,36-40]. The level of evidence 
supporting TDM program for these antibiotics is strong with increasing interest in further 
demonstrating its impact on clinical outcomes [41].
Associated with this increasing interest in -lactam TDM, there has been an increasing effort 
to develop a rapid and efficient assay method to enable quick decisions on dose adjustment.
A convenient assay method for routine use should have a short turnover time while using less 
sophisticated, cheap and easy to use instrumentation. For aminoglycoside antibiotics, 
immunochemical assays provide such an advantage. However, no such techniques are 
available for -lactam antibiotics and previous attempts to develop such methods have been 
difficult [42,43]. Most of the studies that have described TDM for these antibiotics utilized 
high performance liquid chromatography (HPLC) assay methods [41]. For a comprehensive 
review of advances in the determination of -lactam antibiotics by liquid chromatography 
using different detector systems, the reader is referred to the paper by Lara et al[44]. In 
general, a number of HPLC methods with ultraviolet detection are described for -lactams 
including simultaneous determination of several -lactams [45-49]. 
Liquid chromatography tandem mass spectrometry (LCMSMS) methods have also been 
described [50-53].The use of mass spectroscopy detectors allows a more definitive 
identification and quantitative determination of compounds, even with low resolution 
chromatography; a future not possible with other methods of HPLC detection [54]. LCMSMS 
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also offers short time of analysis and is generally regarded as superior to HPLC methods 
because risk of false positive results is minimal. However, there are few LCMSMS methods 
for -lactams that can analyse more than three analytes simultaneously in human plasma with 
many of the methods focusing on a single or few (two or three) analyte combinations. Further 
to this, the existing simultaneous methods do not encompass all relevant antibiotics as far as 
TDM in critical care is concerned. For example the method by Ohmori et al [50] can analyse 
eight -lactams simultaneously. However this method does not include all commonly used 
drugs such as benzylpenicillin, ertapenem, ceftazidime and flucloxacillin which are of 
interest in -lactam TDM and included in the present method. A method by Ahsman et al
[51] described analysis of six -lactams. Two of these, cefotaxime and deacetylecefotaxime, 
are not commonly used in intensive care units and thus are less relevant as far as application 
to TDM is concerned. The method by Carlier et al [52]can analyse 7 beta-lactams but does 
not include bezylpenicillin and ertapenem which were of interest in our TDM program. 
The aim of this paper is to describe a newly developed, precise, accurate and reproducible 
LCMSMS method for simultaneous analysis of seven -lactam antibiotics; three penicillins 
(benzylpenicillin, piperacillin, flucloxacillin), two carbapenems (meropenem, ertapenem) and 
two cephalosporins (cephazolin, ceftazidime). The combination of antibiotics selected in this 
study is different from previously described simultaneous LCMSMS methods and is aimed at 
those common antibiotics used in severely ill patients such as those in the intensive care unit 
(ICU) or with malignancy so as to enable the method applicable for TDM or pharmacokinetic 
studies.
2. Materials And Methods
2.1 Chemicals and reagents
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The drug materials were obtained as formulations for injections: piperacillin sodium 
(Tazocin, Pfizer Australia Pty Ltd); benzylpenicillin sodium (BenPen, CSL Limited); 
flucloxacillin sodium (Flucil, Aspen Pharmacare Australia); meropenem trihydrate (DBL 
Meropenem for injection, Hospira Pty Ltd  Australia); ertapenem sodium (Invanz, Merck 
Sharp and Dohme); cephazolin sodium (Kefzol, Aspen Pharmacare Australia); ceftazidime 
pentahydrate (DBL ceftazidime for injections, Hospira Pty Ltd Australia); fluconazole, 
sodium chloride solution for injection (Aspen Pharmacare, Australia); acetonitrile HPLC 
grade (Optigen Scientific, Australia), methanol especially purified for HPLC (Ajax 
Finechem, Australia); formic acid for HPLC (Sigma-Aldrich, USA). Blank plasma was 
obtained from patients undergoing plasmapheresis at the Queen Elizabeth Hospital, Adelaide, 
South Australia. All water used was purified by reverse osmosis (Cascada™ RO-Water 
Purification System, Pall Life Sciences).
2.2 Instrumentation
The LCMSMS system used for analysis included a Shimadzu LC system combined with a 
triple quadrupole mass spectrometer API 3000 (Applied Biosystems–ABSciex, Foster City, 
CA, USA) equipped with an electrospray ionization source. The LC system was composed of 
two pumps for gradient flow (Model: LC-20AD) with a binary flow pumping mode at a rate 
of 0.3 mL/min and was equipped with a temperature controlled auto-sampler (Model: SIL-
20AC), column oven (Model: CTO-20A), system controller (Model: CBM-20A) and on-line 
solvent degasser (Model: DGU 20A5). A reversed phase kinetex® C18 column with 
trimethylsilyl endcaping (Phenomenex, Part No. 00B-4462-AN, 2.6µm, 2.1* 50 mm) was 
used for chromatographic separation in combination with a pre-fitted in-line filter for column 
protection (Phenomenex, AFO-8497 KrudKatcher). Analyst software version 1.5 run on 
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Windows XP Professional was used for instrument control, data acquisition and data 
processing. 
2.3 Chromatographic and mass spectroscopic conditions
20 L of sample was injected into the LC system. Auto-sampler and column temperature 
were maintained at 4 °C and 35 °C, respectively. Chromatographic separation was performed 
by gradient elution using mobile phase A (water containing 0.1 % formic acid) and mobile 
phase B (acetonitrile containing 0.1% formic acid) with a total flow rate of 0.3 mL/min 
(Figure 1). Mobile phase B was kept at 0% from 0.0 min to 0.1 min, then increased linearly to 
85% from 0.1 to 2.0 min. It was held at 85% from 2.0 to 5.5 min and then decreased linearly 
back to 0% from 5.5 to 6.0 min and finally held at 0% from 6.0 to 7.0 min. Flow was diverted 
to waste for the first 2.7 and after 4.9 minutes. The total run time was 7.0 minutes. 
MSMS detector analysis was performed in positive mode with electrospray ionization. Direct 
infusion of 100 g/mL of each analyte in mobile phase A was made to optimise parameters to 
detect the most intense signals of transitions from parent to product ions; which were 
subsequently monitored using multiple reactions monitoring (MRM) mode. Compound 
specific parameters for each transition are given in Table 1. Other working parameters 
maintained during analysis include curtain gas (CUR) 12 psi, collision activated dissociation 
(CAD) 10 psi, focusing potential (FP) 360 V, ion spray voltage (IS) 4200 V and the 
temperature of the turbo gas was set at 350 °C. Nitrogen was used as the nebulizer, auxiliary, 
collision and curtain gases. Dwell time was set at 100 ms for each mass transition.
2.4 Preparation of solutions, standards, and quality control samples
Vials of each antibiotic containing powder for injection were initially reconstituted with 5 mL 
of water and then were subsequently diluted to 10 mL with water to give seven primary stock 
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solutions ranging from 50 mg/mL to 400 mg/mL. The primary stocks were then diluted with 
water to give 5 mg/mL standard solutions for each antibiotic and were stored in 1 mL aliquots 
at -80 °C under which condition -lactams are known to be stable at least for few months 
[45,46,50,51]. These standard solutions were used to prepare fresh standards and QCs in 
plasma for every analytical run. 
To prepare standards and QCs in plasma firstly, an intermediate 500 g/mL solution 
containing all the seven -lactam antibiotics was prepared by combining appropriate volumes 
of each 5 mg/mL standard solution (e.g. 250l of each 5mg/mL solutions were combined and 
diluted with 750l of water to give 500g/ml combined solution). Secondly, this combined 
solution was diluted with water to give drug concentrations of 400, 250, 200, 100, 75, 50, 25, 
10, 7.5, 5, 2.5 and 1 g/mL. Finally, each of these combined -lactam solutions were then 
diluted with drug-free blank plasma in a 1 : 9 ratio to give working standards and quality 
control samples. Plasma working standards (300l each) were prepared at drug 
concentrations of 50, 25, 10, 5, 2.5, 1, 0.5, 0.25 (flucloxacillin only) and 0.1 g/mL.  Plasma 
quality control samples were prepared independently at a concentration of 40, 7.5, 0.75 and 
0.25 g/mL (for meropenem, ertapenem, cefazolin and ceftazidime) and at a concentration of 
20, 7.5, 0.75, and 0.25 g/mL (for benzylpenicillin and piperacillin). Flucloxacillin 
concentrations for quality control samples were 20, 7.5 and 0.75 g/mL.  
The internal standard (fluconazole) stock solution was prepared by diluting the 2 mg/mL 
solution for injections (available in vials) with water to give a 5 g/mL solution. Aliquots of 
1 mL containing 5 g/mL solution were stored at -80 °C until used. 
2.5 Sample Preparation
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Protein precipitation  by acetonitrile containing 0.1% formic acid  was used for sample 
preparation after testing various protein precipitants at different plasma to precipitant ratios as 
recommended by Polson et al. for human plasma [55].
During sample preparation, 15 L of 5 g/mL internal standard (Fluconazole) was added to 
each 300 l standard calibrators and quality control samples put in 1.5 mL microcentrifuge 
tubes, and the samples were subsequently vortex mixed for 20 seconds. Plasma proteins were 
then precipitated by adding 600 L of acetonitrile containing 0.1% formic acid and vortex 
mixed for about 30 seconds. The precipitant was separated by centrifugation at 12000  g for 
six minutes at 4 °C (Sigma, 1-15K; Germany). 400 L of the upper clear supernatant was 
then transferred into another 1.5 mL tube and diluted in 1 : 1 ratio with 400 L of water 
containing 0.1% formic acid . After vortex mixing for 20 seconds, 300 L was transferred 
into a flat bottom autosampler insert. The autosampler vials were then sealed with caps 
(SUN-Sri, Thermo Fisher Scientific Inc.) fitted with white PTFE septa (8-425 closure, Grace 
Davison Discovery Science).
2.6 Validation of the method. 
Validation of the method was conducted in accordance with guidelines of the National 
Association of Testing Authorities, Australia (NATA) [56] and the Food and Drug 
Administration (FDA)[57]. 
2.6.1 Calibration curve and limit of quantification
Calibration curve was examined by running five sets of standard calibrators on five different 
days. For this validation each standard calibrator was analysed in five replicates. Calibration 
curves were generated by plotting the ratio of nominal concentration of the standard to that of 
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internal standard versus the ratio of the standard peak area to the internal standard peak area. 
Different regression modes in combination with different weighting approaches were tested 
to select the best fit to the data. The acceptance criterion for calibration curve was that at least 
75 % of standards should have acceptable accuracy and precision [58]. Accuracy was 
considered acceptable when deviations of the mean values of back calculated concentration 
from the nominal concentrations were within 15% for all standards except at the lower limit 
of quantification (LLOQ) where 20% was considered acceptable. Similarly, acceptable 
precisions were those with the coefficient of variation (CV) less than 15% except at the 
LLOQ, where it was less than 20%. The limit of quantification was validated by analysis of 
five replicates prepared independently of the standards with less than 20% relative standard 
deviation as well as less than 20% deviation from the nominal concentration as acceptance 
criteria [57].  
2.6.2 Accuracy and precision.
The intra-day and inter-day accuracy and precision were assessed by using five concentration 
of QCs including the LLOQ run in five replicates.  For flucloxacillin four concentrations of 
QCs were used. The intra-day data was collected by running two sets of calibrators and QCs 
within a day and the inter-day data was collected by running five sets of QCs with calibrators 
on five different days. 
2.6.3 Recovery, matrix effect and specificity
Recovery (extraction efficiency) was determined at four QC levels run in five replicates each 
by comparing the peak areas of each analyte in spiked plasma samples with those of samples 
to which the same amounts of analyte was added after protein precipitation. Matrix effect was 
examined in two ways. Firstly, QC samples at four different concentrations (three for 
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flucloxacillin) were prepared in plasma from six different donors and quantified using freshly 
spiked calibration curve. The accuracy and precision of calculated concentrations in reference 
to the nominal concentrations were then determined for each QC[59]. Secondly, the matrix 
effect was quantified according to the procedures demonstrated by Matuszewski et al.[60]. 
Analytes were spiked in post extraction matrix from six different plasma donors at three 
concentrations in duplicate; and in water as a ‘neat solution’. Matrix effect was then 
calculated as the ratio of peak area obtained from post-extraction matrix samples to that of 
water samples expressed as percentage. Internal standard normalized matrix effect was also 
calculated from the six different lots of plasma by dividing the matrix effect of each analyte 
by the matrix effect of the internal standard. Specificity of the method was ascertained using 
six different sources of plasma and comparing chromatograms of blank plasma with the 
corresponding spiked plasma samples. 
2.6.4 Stability
Bench top stability of samples in plasma was tested by preparing QCs at four different 
concentrations (three for flucloxacillin) in five replicates and analysing them after four hours 
of stay on the bench at room temperature prior to extraction. Accuracy and precision were 
determined using back calculated concentrations from an original standard curve plotted with 
freshly prepared and extracted standards. 
Post preparative stability (auto-sampler stability) was examined using four QCs  prepared and 
extracted in five replicates and stored in sealed auto-sampler vials in a cold room at 4 °C 
(auto-sampler temperature) for twelve hours before analysis. Samples were spiked after 
twelve hrs and the accuracy and precision were determined using back calculated 
concentrations from an original standard curve plotted with freshly prepared and extracted 
standards. 
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Freeze and thaw stability was also assessed using QCs at four concentrations prepared in five 
aliquots. Analyte stability was determined after three freeze-thaw cycles: Aliquots of the QCs 
were initially frozen at -80 °C for twenty four hours and then allowed to thaw unassisted at 
room temperature. When completely thawed, samples were refrozen again at the same 
temperature for about sixteen hrs. Samples were then thawed similarly and refrozen for 
another cycle for about sixteen hrs after which they were thawed, extracted and analysed 
together with freshly prepared and extracted standards.  Accuracy and precision were 
determined using back calculated concentrations.
2.6.5 Incurred samples analysis 
Incurred samples analysis was performed in accordance with the European Medicine Agency 
(EMEA) guideline [58]. Twenty five previously analysed patient samples were reanalysed on 
different days in separate runs. Samples were randomly selected for re-analysis and were 
around Cmax and in the elimination phase. Percent deviation of concentrations obtained for the 
initial analysis and the concentrations obtained by reanalysis from their respective means 
were determined.
2.7 Application: Analysis of patient samples. The current method is being used for ongoing 
study of TDM of -lactam antibiotics in critically ill patients receiving antibiotic therapy in 
intensive care unit at The Queen Elizabeth Hospital, Adelaide, Australia. Ethics approval for 
the study was granted by the Human Research Ethics Committees (HREC) of the Queen
Elizabeth Hospital (TQEH) (Ref. No. HREC/12/TQEHLMH/14) and the University of South 
Australia (UniSA) (Application ID: 0000031080). For assessment of pharmacodynamic 
target attainment, corrections for protein binding were made based on analyses of protein
binding performed in critically ill patients (data submitted) or published protein binding data. 
Accordingly for piperacillin unbound concentrations were determined from the 
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corresponding total concentrations by the equation y= 0.885x -4.813, where y is unbound 
(free) plasma concentration and x is the total plasma concentration. This method has also 
been applied to a pharmacokinetic study of piperacillin in patients with haematological 
malignancies who succumb to febrile neutropenia. Ethics approval for this study was granted 
by the HREC of TQEH (Ref. No. HREC/12/TQEHLMH/157) and UniSA (Application ID: 
0000031077).
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 3. Results  
3.1 Sample preparation, chromatography and mass spectrometry
Upon screening for protein precipitation efficiency and effect on the stability of -lactams, 
10% (w/v) trichloroacetic acid (TCA) in 0.5 : 1 ratio, acetonitrile in 2 : 1 ratio and methanol 
in 2 : 1 ratio showed comparable pellet size (data not shown). This is in accordance with 
previous reports of comparable percent protein precipitation, 91%, 92% and 90%, 
respectively [55]. However, 10% TCA appears to affect stability, particularly for meropenem. 
Both acetonitrile and methanol proved to be favourable as a protein precipitant. However 
acetonitrile was chosen because of the better peak shapes that resulted with the mobile phase 
combination used in this study. 
The mobile phase combination and gradient for the HPLC system were optimised by 
alternating the organic mobile phase B between acetonitrile and methanol (each containing 
0.1 % formic acid) and comparing the different precipitation methods and the symmetry of 
chromatogram peak shapes. With methanol as mobile phase B, while using supernatant as 
injectate after acetonitrile protein precipitation, peak shapes were inconsistent with multiple 
peaks appearing for some analytes.  Acetonitrile was finally chosen as mobile phase B due to 
very good peak shapes consistent across all analytes as well as a significant reduction in the 
instrument operational pressure in comparison with methanol. 
A representative chromatogram with simultaneous analysis showing typical peak shapes for 
each analyte is depicted in Figure 2. All of the seven analytes including the internal standard 
eluted after 3.4 minutes within a one minute interval. Further chromatographic separation was 
not required as the mass to charge ratios were distinct with no cross-talk for each analyte and 
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therefore allow monitoring of unique transitions for MSMS analysis in MRM mode. The 
internal standard fluconazole is eluted in the middle, 40 seconds apart from flucloxacillin and 
within 30 seconds of the rest of the analytes. It is therefore, a suitable common internal 
standard for all of the analytes. For analysis of samples from patients receiving fluconazole 
treatment, one of the analytes can potentially serve as internal standard for the others. For 
example we have validated and used (data not shown here) benzyl penicillin as internal 
standard with this method. 
3.2 Calibration curve and limit of quantification
The calibration curves generated by the ratio of peak areas of standards to that of internal 
standard at eight standard concentration (seven for benzyl penicillin, piperacillin and 
flucloxacillin) showed that quadratic regression with a weighting scheme of 1 / (x * x) best 
described the data set generated for all the seven analytes. The calibration range was from 0.1 
to 50 g/mL for meropenem, ertapenem, ceftazidime and cephazolin; 0.1 to 25 g/mL for 
benzylpenicillin and piperacillin; and 0.25 to 25 g/mL for flucloxacillin. Table 2 shows the 
data for five calibration curves.  The mean regression coefficient (r2) for all standard curves 
was greater than 0.99 and this high correlation is consistent with very low standard deviation 
(0.1% to 0.4%). There is variation, however, in the coefficients of quadratic equations from 
run to run. It is, therefore, necessary to include standards together with QCs in every run of 
data analysis [57]. Mean coefficients and standard deviations from the five inter-day runs are 
given in Table 2.
The LLOQ for all analytes was 100 ng/mL except for flucloxacillin for which it was 250 
ng/mL. The LLOQs are sufficiently lower than expected trough concentration or real plasma 
levels [61-66] and therefore the method can accurately determination concentrations in the 
expected low ranges. Concentrations above the upper limit of quantification can be diluted 
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with blank drug free plasma as needed to put the concentration in the range of the calibration 
curve. Figure 3 depicts typical chromatograms of each analyte at the LLOQ. The signal to 
noise ratio at the LLOQ for all analytes was greater than 5 : 1.
3.3 Accuracy, precision and recovery
Table 3 shows a summary of accuracies and precisions for intra-day and inter-day runs. For 
all analytes, mean accuracies of the intra-day QC samples ranged from 95% to 107% while 
that of LLOQ samples range from 88% to 108%. The CV for all intra-day QC samples 
ranged from 4 to 12 %. The CVs for LLOQ were also less than 12% for all analytes except 
flucloxacillin for which it was 15%. The mean inter-day accuracies ranged between 95% to 
108 for all QCs including the LLOQs with the CVs ranging from 5% to 14%. In general the 
method is accurate and precise for each antibiotic as per the requirements of the FDA and 
NATA guidelines [56,57]. The mean recovery at all QC concentrations was greater than 96% 
for all analytes except for ertapenem for which 78% recovery was noted (Table 2). Though 
relatively low, the recovery of ertapenem is sufficiently high and the analyte demonstrated 
good sensitivity, precision and accuracy. Generally, the extent of recovery is not considered 
as an issue in bioanalytical method development given adequate sensitivity, precision and 
accuracy[67].  
3.4 Stability
Table 4 summarizes the percent accuracy and coefficient of variation for bench-top, post-
preparative and freeze-thaw stability evaluation at the various QC concentrations. In general, 
the antibiotics were stable under the conditions tested with the percent accuracy and 
coefficient of variations falling in the acceptable ranges, 85%-115% and within 15%, 
respectively.
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3.5 Matrix effect
The mean accuracies of all QC samples run in plasma from six different donors were all 
within 10% of the nominal concentration and ranged 95-100% for benzylpenicillin, 93-100% 
for ceftazidime, 98-101% for cephazolin, 96-105% for ertapenem, 94-100% for 
flucloxacillin, 93-103% for meropenem and 90-104% for piperacillin. The mean coefficient 
of variation was also within the acceptable limit (less than 15%) for each analyte at each QC 
concentration indicating no significant variability in analyte signal due to difference in the 
source of plasma. Quantitative analysis showed notable matrix effect (Figure 4), particularly 
for meropenem and ceftazidime which also have the smallest retention times of all the 
analytes. The highest matrix effect observed for meropenem is comparable to that reported by 
Ahsman et al.[51] using a procedure that involves acetonitrile protein precipitation. The 
matrix effect for the internal standard (fluconazole) was negligible. The internal standard 
normalized matrix effect was comparable to the matrix effect observed for each analyte 
(Figure 4). CV of normalized matrix effect was less than 15% for each analyte. Despite 
variable among analytes, the matrix effect was consistent for each analyte. There was no 
variation among the six different batches of plasma with less than 10% CV of the mean 
matrix effect for each analyte.  This finding supports the above observation of good precision 
and accuracy of QC samples spiked in six different batches of plasma against a standard 
curve. 
3.6 Selectivity
Representative chromatograms of the blank and double blank plasma samples are given in 
Figure 5. Analyte signals of spiked blank plasma samples can be seen at their respective 
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retention times in Figure 3. The absence of any interfering signal from endogenous 
compounds in the drug free human plasma at the retention times of the analytes and the 
internal standard (in Figure 5) indicates the selectivity or specificity of the method. 
3.7 Incurred sample analysis 
For each of the twenty-five samples subjected to incurred sample reanalysis, the 
concentration obtained for the initial analysis and the concentration obtained by reanalysis 
were within 20% of their mean. I.e. 100% of the repeats resulted in concentration within the limits 
of EMEA guideline.
3.8 Analysis of patient samples
The developed method has proved successful in the analysis of patient samples for TDM. 
Daily TDM was performed using this method for patients admitted to ICU. Figure 6 A and B 
illustrate the steady state plasma concentration profile (corrected for protein binding) after 
daily TDM of piperacillin-tazobactam (4.5 g via intravenous intermittent infusion every eight 
hours) in a patient for four consecutive days and in four different patients after first TDM 
respectively. Peak concentrations were determined by sampling immediately after the end of 
bolus infusion (ranged from 30 min-63 min) and varied 121 to 254 mg/L for these patients. 
Variable peak concentrations have been observed in critically ill patients (not relevant to 
efficacy and also depends on variable bolus infusion and sampling time); e.g. 178-316 mg/L 
at steady state by Roberts et al.[5], 72 to 179 mg/L in the first 24hr of dosing by Taccone et 
al.[4]. As the time free concentrations remains above MIC is more important for efficacy of 
-lactams, intermediate samples taken at specific times in the dosing interval can allow 
determination of the specific pharmacodynamic target considered, e.g. free concentration 
greater than MIC for 50% of the dose interval (50% fT>MIC), and trough concentration just 
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before the next dose enable assessment of the attainment of more robust pharmacodynamic 
targets (i.e. 100% fT>MIC or 100% fT>4-5xMIC). The trough concentrations that were observed 
(Figure 6) ranged from 8 to 20 mg/L and are in agreement with previous reports [12]. 
Similarly, figure 7 shows unbound concentration profile of meropenem in a critically ill 
patient with renal dysfunction undergoing continuous venovenous haemodiafiltration after 
TDM for two consecutive days.  
The method has also been applied to a pharmacokinetic study of piperacillin. Figure 8 depicts 
the total plasma concentration profile of piperacillin after a single dose administration of 4.5g 
Tazocin® via intravenous bolus infusion (over 30 min) in twelve patients with 
haematological malignancy who succumbed to febrile neutropenia following high dose 
chemotherapy. 
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4. Discussion
We present a method for the simultaneous determination of seven -lactam antibiotics 
commonly used in severely ill patients such as those in the ICU or with malignancy. The 
ability to simultaneously assay several antibiotics in a single analytical run is of great 
advantage to ensure the practicality of a method for routine use as it enables samples from 
different patients receiving different antibiotics to be assayed together at the same time. Time 
is saved by combining multiple analytes with the same standard curve analysis. For the 
purposes of routine TDM, given the need of short turn-over time, it would be impractical to 
individually assay samples from different patients receiving different -lactam antibiotics. 
Even though TDM of -lactam antibiotics is not yet part of standard patient care, evidence is 
increasingly suggesting its benefits in ICU patients and hence the need of for an efficient and 
rapid assay method is growing [41].
A simple sample preparation procedure is important to minimize sample turnover time. In the 
present method, acetonitrile containing 0.1% formic acid has been added to plasma in a 2 : 1 
ratio for protein precipitation. It allowed a simple and efficient protein extraction process 
with excellent analyte recoveries. Protein precipitation using acetonitrile alone [68], 
acetonitrile followed by formic acid [51] or organic extraction [69] has been described earlier 
for -lactam antibiotics. Acetonitrile is one of the most efficient protein precipitants 
particularly at precipitant to plasma volume ratios of 2 : 1 or greater and has excellent 
reproducibility. It is also the precipitant of choice among organic solvents due to its lowest 
ionization suppression effect [55]. To ensure good peak shape of all analytes and maintain the 
retention time, it was found necessary to add water containing 0.1 % formic acid in 1 : 1 ratio 
to the supernatant after precipitation. The addition of 0.1% formic acid in the water for 
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dilution as well as the precipitant improved peak shapes and may enhance ionization 
efficiency of analytes[70]. In addition, the auto-sampler stability may be better for some -
lactams with 0.1% formic acid, particularly meropenem which appears to be the least stable 
of all analytes. Ahsman et al.[51] reported that twenty four hour degradation was better for 
meropenem when it was reconstituted in 0.1% formic acid as compared to pure water (after 
acetonitrile protein precipitation).  
Analyte stability is a significant challenge in the development of assay methodology for -
lactams and may restrict the choices of mobile phase and various efficient protein precipitants 
that could be used in LCMSMS.  For example, there has been a concern on the use of 
methanol as a mobile phase amid reports of relative instability of -lactams in methanol as 
compared to acetonitrile[71] , while Kantiani et al. [72] showed that this may be unlikely as 
the chromatographic run time is often less than 10 minutes, a time period not sufficiently long 
for the compounds to undergo any degradation . Despite such concerns, methanol has been 
used even as the protein precipitant in LCMSMS methods for some -lactams with prolonged 
exposure [73,74]. While further study on the effect of methanol on individual - lactams 
(possibly differential effect) is warranted, we avoided it both as a mobile phase and as a 
precipitant. Among other precipitants tested, 10% TCA led to noticeable degradation possibly 
because, in the presence of an acid in high concentration, degradation of -lactams is very 
likely due to instability of the four member -lactam ring [44,75]. -lactams are also unstable 
when zinc sulphate is used as a precipitant despite the latter being very efficient protein 
precipitant [55]. Zinc has been shown to catalyse degradation of penicillins [76]. Potentially 
it could also affect analyte ionization and MS interface integrity requiring solvent diversion 
to waste to reduce involatile salt build up[55].
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-lactams are known to achieve efficient ionization via the electrospray technique and 
therefore would undergo easy ionization from the TurboIonSpray® source used in this 
method. Positive ionization mode was used because, generally most of the -lactams have 
higher sensitivity in positive mode [44]. However  they are amenable to negative ionization 
given the fact that all contain a carboxylic acid moiety and for some, negative mode has been 
reported [77] to produce a high signal to noise ratio. In positive ion mode, both -lactam class 
specific fragments of m/z 160 and compound specific fragments [M + H – 159]+ are 
produced together with other fragments including adducts of sodium and methanol [ 
M+CH3OH + H]+ [44] providing a wide choice for monitoring of unique ion-transitions 
using tandem-mass spectroscopic technique coupled to the HPLC system. The transitions 
from Q1 to Q3 were distinct for each anayltes in the current method with similar Q3 used 
only for benzylpenicillin and flucloxacillin for which there was no ‘cross-talk’ with clear 
baseline resolution.   
Across the concentration ranges of the established calibration curves, the precision and 
accuracy of this method meet the requirements guidelines for bioanalytical method 
development [56,57]. The accuracy is not affected by the storage condition as the three 
freeze-thaw cycles met stability criteria. Additional confirmatory tests are possible if the need 
arises or if reanalysis is necessary for any reason.  As sample preparation is simple and does 
not take a long time, concerns of bench-top stability may not be an issue with this method. In 
our method, twelve hour post-preparative stability was acceptable for all analytes.  However, 
when instability is identified, large sample runs must be validated particularly for those -
lactams with known limited stability, specifically meropenem and ertapenem. 
Despite the notable matrix effect observed, particularly for meropenem and ceftazidime, 
signal intensity was importantly consistent across the six batches of plasma tested and did not 
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affect the desired LOQ levels to detect clinically relevant concentrations. Practically, since all 
the calibration samples are always run in plasma, much of the matrix effect noted (by 
comparing peak area against neat solution) is duly accounted for as long as there are no 
variations across different batches. In the current method, there was no such variation with 
the accuracy and CV of QC samples run in six different batches of plasma falling within the 
limits of guidelines. This indicates that no further sources of variation arise due to the use of 
different plasma sources. Therefore, estimates of plasma concentration quantified using this 
method from clinical samples of different patients can be considered reliable and comparable. 
5. Conclusion 
The method presented here is accurate, precise and reliable for the determination of 
piperacillin, benzylpenicillin, flucloxacillin, meropenem, ertapenem, cephazolin and 
ceftazidime in human plasma. It has been successfully applied to a pharmacokinetic study 
and therapeutic drug monitoring proving reproducibility. Complementary to the few 
simultaneous LCMSMS methods available for -lactams, it offers an advantage by 
combining the most common antibiotics for which there is an increasing TDM interest in the 
critically ill. It, thus, provides an important alternative for research and clinical analysis of the 
unique combination of -lactams presented. 
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Table 1. Compound specific instrument parameters.
t1.1
Antibiotic 
Molecular 
Weight 
(g) 
Precursor 
Ion   
(Q1)
Product 
Ion 
(Q3)
Declustering 
Potential 
(DP) V
Entrance 
Potential 
(EP) V
Collision 
Energy 
(CE) eV
Collision 
Cell Exit 
Potential 
(CXP) V
t1.2 Meropenem 383.5 384.3 114.1 15 4 37 2
t1.3 Ertapenem 475.5 476.9 432.9 8 6 14 33
t1.4 Ceftazidime 546.5 547.2 167.1 10 5 31 4
t1.5 Cephazolin 454.5 455.4 156.1 5 6 21 3
t1.6 Benzylpenicillin 334.4 335.6 160.2 15 7 19 11
t1.7 Piperacillin 517.5 519 143.1 15 7 23 11
t1.8 Flucloxacillin 453.9 454.6 160.1 15 7 23 11
t1.9 Fluconazole (IS
a
) 306.3 307.3 127.1 54 10 40 19
a Internal standard
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Table 2. Summary of standard curves, retention times and extraction efficiency.1
t2.1 Quadratic coefficient Linear coefficient Constant r
2 Extraction Efficiency
t2.2 Antibiotics 
Mean SD Mean SD Mean SD Mean
SD 
(%)
Range 
(g/ml)
Retention 
time    
(min)
% 
Recovery
% 
Deviation 
t2.3 Meropenem 1.35E-09 5.74E-10 3.07E-04 5.42E-05 -5.05E-03 0.006234 0.992 0.3 50-0.1 3.4 101 6.5
t2.4 Ertapenem 8.65E-10 6.48E-10 2.34E-04 2.26E-05 -1.13E-03 0.004336 0.992 0.3 50-0.1 3.5 78 6.6
t2.5 Ceftazidime 7.44E-10 4.23E-10 1.53E-04 1.08E-05 -5.66E-04 0.002473 0.992 0.2 50-0.1 3.4 96 5.6
t2.6 Cephazolin -1.47E-09 6.75E-10 3.36E-04 4.04E-05 -1.15E-03 0.003106 0.996 0.1 50-0.1 3.8 107 5.6
t2.7 Benzylpenicillin -9.11E-09 2.27E-09 6.73E-04 8.28E-05 -2.93E-03 0.007398 0.993 0.3 25-0.1 4.2 96 4.8
t2.8 Piperacillin -2.96E-09 1.37E-09 2.38E-04 3.08E-05 8.36E-04 0.002629 0.992 0.4 25-0.1 4.1 98 4.1
t2.9 Flucloxacillin -1.91E-09 3.83E-10 1.29E-04 1.21E-05 1.64E-03 0.001536 0.992 0.4 25-0.25 4.4 98 4.7
t2.10 Fluconazole (Internal Standard) 3.7 106 5.5
2
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Table 3. Summary of accuracy and precision for intra-day and inter-day runs. 1
t3.1 Intra-day Inter-day 
t3.2 Antibiotic Concentration Mean 
Accuracy 
(%)
Mean 
CV     
(%)
Mean 
Accuracy 
(%)
Mean 
CV     
(%)
t3.4 Meropenem 100ng/ml (LLOQ) 103 10 105 10
t3.5 250ng/ml 102 10 101 7
t3.6 750ng/ml 103 6 100 7
t3.7 7500ng/ml 103 7 100 6
t3.8 40000ng/ml 100 8 96 7
t3.9 Ertapenem 100ng/ml (LLOQ) 88 11 97 14
t3.10 250ng/ml 96 7 101 10
t3.11 750ng/ml 98 12 102 7
t3.12 7500gn/ml 99 7 103 6
t3.13 40000ng/ml 103 4 99 6
t3.14 Ceftazidime 100ng/ml (LLOQ) 97 12 102 14
t3.15 250ng/ml 107 8 105 10
t3.16 750ng/ml 105 5 99 6
t3.17 7500gn/ml 98 4 99 5
t3.18 40000ng/ml 100 6 97 8
t3.19 Cephazolin 100ng/ml (LLOQ) 92 11 99 7
t3.20 250ng/ml 104 8 105 9
t3.21 750ng/ml 103 6 102 7
t3.22 7500gn/ml 102 4 99 5
t3.23 40000ng/ml 99 7 95 7
t3.24 Benzylpenicillin 100ng/ml (LLOQ) 93 9 105 9
t3.25 250ng/ml 106 6 102 8
t3.26 750ng/ml 105 5 100 7
t3.27 7500gn/ml 96 7 99 5
t3.28 20000ng/ml 101 6 103 11
t3.29 Piperacillin 100ng/ml (LLOQ) 99 11 102 14
t3.30 250ng/ml 102 11 108 11
t3.31 750ng/ml 103 7 98 14
t3.32 7500gn/ml 95 8 98 7
t3.33 20000ng/ml 103 8 99 9
t3.34 Flucloxacillin 250ng/ml (LLOQ) 108 15 100 13
t3.35 750ng/ml 104 11 101 11
t3.36 7500gn/ml 96 7 96 5
t3.37 20000ng/ml 98 7 102 11
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Table 4. Summary of accuracy and precision of QCs for bench-top, freeze-thaw and post-preparative stability studies. (Values represent mean % 1
accuracy / % CV)2
a 20000ng/ml for benzylpenicillin, piperacillin and flucloxacillin3
t4.1 Bench-top stability (4hrs) Freeze-Thaw  stability (-80 °C) Post-Preparative  stability (12hrs)
t4.2
40000/ 
20000a
(ng/ml)
7500  
(ng/ml)
750 
(ng/ml)
250 
(ng/ml)
40000/ 
20000a
(ng/ml)
7500  
(ng/ml)
750 
(ng/ml)
250 
(ng/ml)
40000/ 
20000a
(ng/ml)
7500  
(ng/ml)
750 
(ng/ml)
250 
(ng/ml)
t4.3 Meropenem 99/4 94/4 93/7 96/8 90/7 110/2 109/13 114/4 92/5 98/4 90/7 86/10
t4.4 Ertapenem 98/4 96/6 106/6 111/12 108/4 107/7 112/7 110/8 91/4 97/4 96/3 95/8
t4.5 Ceftazidime 91/4 89/5 105/8 105/7 102/5 109/11 102/4 98/7 105/4 111/7 105/5 103/5
t4.6 Cephazolin 102/3 94/2 108/4 105/8 109/6 108/4 107/5 110/5 105/4 103/5 100/5 109/8
t4.7 Benzylpenicillin 100/11 90/8 100/8 100/6 113/13 105/5 108/5 108/2 99/13 94/7 90/3 97/3
t4.8 Piperacillin 90/7 90/4 110/7 102/12 105/10 104/7 107/4 113/12 104/9 100/5 95/4 104/11
t4.9 Flucloxacillin 100/7 91/7 104/12 - 105/8 106/5 113/12 - 110/9 98/9 97/12 -
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Figure 1. Gradient Curve1
Figure 2. Representative chromatogram of the seven -lactams and the internal standard 2
fluconazole run simultaneously. 3
Figure 3. Typical chromatogram of each analyte at their respective lower limit of 4
quantification. 5
Figure 4. Matrix effect of analytes. Values represent averages with the corresponding 6
95% confidence intervals. 7
Figure 5. Representative chromatograms of blank (A) and double blank (B) plasma 8
samples. 9
Figure 6. Steady state free plasma concentration profile of piperacillin after daily TDM in 10
a patient receiving 4.5 g Tazocin® every eight hours (A), and after first TDM in four 11
different patients (B).  MIC marked is for Pseudomonas aeruginosa.12
Figure 7. Free plasma concentration profile of meropenem in a patient undergoing 13
continuous venovenous haemodiafiltration (TDM-1 after 1g IV every 12 hr dosing; 14
TDM-2 after 1g IV every 8hr dosing).15
Figure 8. Total plasma concentration profile of piperacillin after single dose 16
administration  of 4.5g Tazocin® IV over 30 minutes in twelve patient with 17
haematological malignancy and febrile neutropenia.18
Page 40 of 48
Ac
ce
pte
d M
an
us
cri
pt
Highlights 
 We present a method for simultaneous determination of seven beta-lactams in plasma 
 The selected antibiotics are those commonly used in critically ill patients  
 The method is accurate, precise and meets validation requirements by guidelines    
 It proved applicable for therapeutic drug monitoring and pharmacokinetic studies   
*Highlights (for review)
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Figure 3
Page 44 of 48
Ac
ce
pte
d M
an
us
cri
ptFigure 4
Page 45 of 48
Ac
ce
pte
d M
an
us
cri
pt
Figure 5
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Page 47 of 48
Ac
ce
pte
d M
an
us
cri
ptFigure 7
Page 48 of 48
Ac
ce
pte
d M
an
us
cri
ptFigure 8
